Ascendis Pharma News and Activities

Ascendis Pharma is a company listed under the stock ticker ASND (DK).

Ascendis Pharma has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Healthcare50%

View the org chart displaying its 26 main executives

Most searched biographies at Ascendis Pharma

• Jan Mikkelsen, Director, President and Chief Executive Officer
• Lars Holtug, Director
• Siham Imani, Board Member

Create your alert
to follow the executive moves at Ascendis Pharma.

Ascendis Pharma has 1,826 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• Danone has announced the acquisition of Kate Farms  (posted on May 14 2025).
• Cyclo Therapeutics has acquired Rafael Holdings (posted on April 28 2025).
• Chimerix and Chimerix have merged  (posted on April 22 2025)..

Popular contacts in Pharmaceuticals

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets at Bristol-Myers Squibb
• Seth Harrison - Chairman and Director at Braeburn Pharmaceuticals
• Fred Davenport - Lead Director at Medpace

Learn more about the Pharmaceuticals industry

Press releases by Ascendis Pharma

• FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency | Ascendis Pharma
• Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism | Ascendis Pharma
• Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA | Ascendis Pharma
• Ascendis Pharma Reports Third Quarter 2023 Financial Results | Ascendis Pharma
• Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission | Ascendis Pharma
• News Releases | Ascendis Pharma
• Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023 | Ascendis Pharma
• Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023 | Ascendis Pharma
• Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting | Ascendis Pharma
• Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency | Ascendis Pharma
• View more press releases Close

Social media about Ascendis Pharma

• Ascendis Pharma on Wikipedia, Google News & Yahoo Finance
• Ascendis Pharma on LinkedIn, Twitter & YouTube